Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
Niewerth D, Kaspers GJ, Jansen G, van Meerloo J, Zweegman S, Jenkins G, Whitlock JA, Hunger SP, Lu X, Alonzo TA, van de Ven PM, Horton TM, Cloos J. Niewerth D, et al. Among authors: zweegman s. J Hematol Oncol. 2016 Sep 6;9(1):82. doi: 10.1186/s13045-016-0312-z. J Hematol Oncol. 2016. PMID: 27599459 Free PMC article. Clinical Trial.
Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
Terwijn M, Kelder A, Snel AN, Rutten AP, Scholten WJ, Oussoren YJ, Van De Loosdrecht AA, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. Terwijn M, et al. Among authors: zweegman s. Int J Lab Hematol. 2012 Aug;34(4):432-41. doi: 10.1111/j.1751-553X.2012.01416.x. Epub 2012 Apr 4. Int J Lab Hematol. 2012. PMID: 22471741
Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.
Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G. Verbrugge SE, et al. Among authors: zweegman s. Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2. Exp Hematol Oncol. 2013. PMID: 23305345 Free PMC article.
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J. Niewerth D, et al. Among authors: zweegman s. Haematologica. 2013 Dec;98(12):1896-904. doi: 10.3324/haematol.2013.092411. Epub 2013 Sep 20. Haematologica. 2013. PMID: 24056819 Free PMC article.
Adherence and patients' experiences with the use of oral anticancer agents.
Timmers L, Boons CC, Kropff F, van de Ven PM, Swart EL, Smit EF, Zweegman S, Kroep JR, Timmer-Bonte JN, Boven E, Hugtenburg JG. Timmers L, et al. Among authors: zweegman s. Acta Oncol. 2014 Feb;53(2):259-67. doi: 10.3109/0284186X.2013.844353. Epub 2013 Nov 22. Acta Oncol. 2014. PMID: 24266637
18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
Wondergem MJ, Rizvi SN, Jauw Y, Hoekstra OS, Hoetjes N, van de Ven PM, Boellaard R, Chamuleau ME, Cillessen SA, Regelink JC, Zweegman S, Zijlstra JM. Wondergem MJ, et al. Among authors: zweegman s. J Nucl Med. 2015 Feb;56(2):216-21. doi: 10.2967/jnumed.114.149625. Epub 2015 Jan 15. J Nucl Med. 2015. PMID: 25593118 Free article. Clinical Trial.
353 results